Vedana Therapeutics Launches With $46 Million Series A Financing to Advance Next-Generation Migraine Therapies
Targeting clinically validated pathways to enable patients to achieve freedom from migraine
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
Star Therapeutics to receive $1.25 billion upfront, with up to $750 million in additional payments upon achievement of sales milestones
Oorja Bio Unveils Clinical Data for ORJ-001, a First-in-Class Therapeutic Targeting Alveolar Epithelial Type 2 (AEC2) Cells for Treatment of Idiopathic Pulmonary Fibrosis (IPF)
ORJ-001 achieved therapeutic exposure and was well tolerated in Phase 1 study, supporting company’s plans to initiate Phase 2 clinical trial in IPF patients
Oorja Bio Launches a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases
Company announces $30 million Series A financing and founding leadership team with expertise in pulmonary drug innovation and track record advancing novel therapies to patients
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer
Veteran biopharma leader joins to help lead Kyverna’s next phase of commercial growth
Recludix Pharma Announces Preclinical Data Demonstrating Efficacy Comparable to Monoclonal Antibodies Targeting IL-4/IL-13 Signaling Pathways and Differentiated Safety Profile of Oral STAT6 Inhibitor REX-8756 (also known as SAR448755) in a Model of Atopic Dermatitis
REX-8756 is an oral, first-in-class orthosteric STAT6 inhibitor currently being evaluated in an ongoing Phase 1 clinical study
Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results
Positive pre-BLA meeting with FDA alignment reached on KYSA-8 single-arm trial in stiff person syndrome (SPS); rolling BLA submission initiated
Capsida to Present Preclinical Data of New Next-Generation, High-Performing Ocular Capsids at ASGCT Annual Meeting
Provides corporate update including appointment of gene therapy expert Romuald Corbau, Ph.D., as Chief Scientific Officer and an update on the CNS programs
Electra Therapeutics Announces First Patient Dosed in Phase 1 Study of Ipsoprubart (ELA026) in T Cell Malignancies
Phase 1 study builds on early signals of anti-tumor activity in patients with refractory T and B cell lymphomas
Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer
Ms. Dac brings more than 30 years of experience successfully executing product launches and scaling commercial organizations for a range of therapeutic areas